Related Experiment Video
Updated: Feb 16, 2026
07:31
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
Published on: May 3, 2021
4.3K
IGF system in sarcomas: a crucial pathway with many unknowns to exploit for therapy
Caterina Mancarella1, Katia Scotlandi1
1Experimental Oncology Lab, CRS Development of Biomolecular Therapies, Orthopaedic Rizzoli Institute, Bologna, Italy.
Journal of Molecular Endocrinology
|December 24, 2017
Summary
The insulin-like growth factor (IGF) system is a promising therapeutic target for sarcomas, particularly Ewing sarcoma. Further research into novel regulators like IGF2BPs, DDRs, and PAPP-A could unlock new clinical strategies.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The insulin-like growth factor (IGF) system regulates critical cellular processes like proliferation, differentiation, and survival.
- While generally disappointing, clinical trials targeting the IGF system have shown promise in specific sarcomas, notably Ewing sarcoma.
Purpose of the Study:
- To review key studies on IGF signaling in sarcomas, highlighting its therapeutic potential.
- To explore novel regulators of the IGF system, including IGF2BPs, DDRs, and PAPP-A, for potential clinical exploitation.
Main Methods:
- Literature review of studies investigating IGF signaling pathways in sarcoma.
- Analysis of the roles of IGF2 mRNA-binding proteins (IGF2BPs), discoidin domain receptors (DDRs), and pregnancy-associated plasma protein-A (PAPP-A) in IGF regulation.
Main Results:
- The IGF system presents attractive therapeutic properties for sarcoma treatment, with notable success in Ewing sarcoma.
- Emerging evidence suggests IGF2BPs, DDRs, and PAPP-A are key regulators of the IGF axis.
Conclusions:
- Understanding the spatial and temporal control of the IGF axis is crucial for advancing sarcoma therapies.
- Further investigation into novel IGF regulators may reveal new therapeutic strategies for sarcomas.
Related Concept Videos
02:38Mitogens and the Cell Cycle
8.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
03:03mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K
01:19Interactions Between Signaling Pathways
7.4K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.4K
01:16TGF - β Signaling Pathway
10.6K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.6K
02:26NF-κB-dependent Signaling Pathway
10.1K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
10.1K